Literature DB >> 28562069

"We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry.

Karine Dubé1, David Evans2,3, Lynda Dee2,4,5, Laurie Sylla6, Jeff Taylor5,7, Asheley Skinner1,8, Bryan J Weiner1,9, Sandra B Greene1, Stuart Rennie10, Joseph D Tucker11,12.   

Abstract

Strategies to control HIV in the absence of antiretroviral therapy are needed to cure HIV. However, such strategies will require analytical treatment interruptions (ATIs) to determine their efficacy. We investigated how U.S. stakeholders involved in HIV cure research perceive ATIs. We conducted 36 in-depth interviews with three groups of stakeholders: 12 people living with HIV, 11 clinician-researchers, and 13 policy-makers/bioethicists. Qualitative data revealed several themes. First, there was little consensus on when ATIs would be ethically warranted. Second, the most frequent perceived hypothetical motivators for participating in research on ATIs were advancing science and contributing to society. Third, risks related to viral rebound were the most prevalent concerns related to ATIs. Stakeholders suggested ways to minimize the risks of ATIs in HIV cure research. Increased cooperation between scientists and local communities may be useful for minimizing risk. Further ethics research is necessary.

Entities:  

Keywords:  HIV cure research; United States; perceptions; treatment interruptions

Mesh:

Year:  2017        PMID: 28562069      PMCID: PMC5771546          DOI: 10.1089/AID.2017.0067

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  64 in total

1.  Can we avoid treatment interruption studies in the search for an HIV cure?

Authors:  Jade Ghosn; Constance Delaugerre
Journal:  AIDS       Date:  2015-07-31       Impact factor: 4.177

2.  Ethics of ART interruption after stem-cell transplantation.

Authors:  Jeremy Sugarman; Sharon R Lewin; Timothy J Henrich; Thomas A Rasmussen
Journal:  Lancet HIV       Date:  2016-01       Impact factor: 12.767

3.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Authors:  Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

4.  Ethics in human subjects research: do incentives matter?

Authors:  Ruth W Grant; Jeremy Sugarman
Journal:  J Med Philos       Date:  2004-12

5.  Clinical Trial Design for HIV Prevention Research: Determining Standards of Prevention.

Authors:  Liza Dawson; Sheryl Zwerski
Journal:  Bioethics       Date:  2014-09-17       Impact factor: 1.898

6.  Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.

Authors:  Dalton Wamalwa; Sarah Benki-Nugent; Agnes Langat; Kenneth Tapia; Evelyn Ngugi; Helen Moraa; Elizabeth Maleche-Obimbo; Vincent Otieno; Irene Inwani; Barbra A Richardson; Bhavna Chohan; Julie Overbaugh; Grace C John-Stewart
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

Review 7.  Now or never? The case for cell-based immunosuppression in kidney transplantation.

Authors:  James A Hutchinson; Edward K Geissler
Journal:  Kidney Int       Date:  2015-03-04       Impact factor: 10.612

Review 8.  Future technologies for monitoring HIV drug resistance and cure.

Authors:  Urvi M Parikh; Kevin McCormick; Gert van Zyl; John W Mellors
Journal:  Curr Opin HIV AIDS       Date:  2017-03       Impact factor: 4.283

9.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

10.  Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.

Authors:  Alison L Hill; Daniel I S Rosenbloom; Edward Goldstein; Emily Hanhauser; Daniel R Kuritzkes; Robert F Siliciano; Timothy J Henrich
Journal:  PLoS Pathog       Date:  2016-04-27       Impact factor: 6.823

View more
  34 in total

1.  Perceptions of HIV Virologic Control Strategies Among Younger and Older Age Groups of People Living with HIV in the United States: A Cross-Sectional Survey.

Authors:  Parya Saberi; Shadi Eskaf; John Sauceda; David Evans; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2020-05-27       Impact factor: 2.205

2.  Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options.

Authors:  Karine Dubé; Danielle M Campbell; Kelly E Perry; John T Kanazawa; Parya Saberi; John A Sauceda; Tonia Poteat; David Evans
Journal:  AIDS Res Hum Retroviruses       Date:  2020-09-14       Impact factor: 2.205

3.  Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies.

Authors:  Jillian S Y Lau; Miranda Z Smith; Brent Allan; Cipriano Martinez; Jennifer Power; Sharon R Lewin; James H McMahon
Journal:  AIDS Res Hum Retroviruses       Date:  2019-12-02       Impact factor: 2.205

4.  The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy.

Authors:  Karine Dubé; Shadi Eskaf; David Evans; John Sauceda; Parya Saberi; Brandon Brown; Dawn Averitt; Krista Martel; Maria Meija; Danielle Campbell; Liz Barr; John Kanazawa; Kelly Perry; Hursch Patel; Stuart Luter; Tonia Poteat; Judith D Auerbach; David A Wohl
Journal:  AIDS Res Hum Retroviruses       Date:  2019-12-04       Impact factor: 2.205

5.  Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria.

Authors:  Holly L Peay; Stuart Rennie; R Jean Cadigan; Angela Gwaltney; Thidarat Jupimai; Nittaya Phanuphak; Eugène Kroon; Donn J Colby; Nuchanart Ormsby; Sinéad C Isaacson; Sandhya Vasan; Carlo Sacdalan; Peeriya Prueksakaew; Khunthalee Benjapornpong; Jintanat Ananworanich; Gail E Henderson
Journal:  AIDS Behav       Date:  2022-01-08

6.  Perceptions of Risks and Benefits of Participating in HIV Cure-Related Research Among Diverse Young Adults Living with HIV in the United States: Qualitative Research Findings.

Authors:  Parya Saberi; Chadwick K Campbell; John A Sauceda; Samuel Ndukwe; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2022-06-28       Impact factor: 1.723

7.  HIV Cure Research: Risks Patients Expressed Willingness to Accept.

Authors:  Allison Kratka; Peter A Ubel; Karen Scherr; Benjamin Murray; Nir Eyal; Christine Kirby; Madelaine N Katz; Lisa Holtzman; Kathryn Pollak; Kenneth Freedburg; Jennifer Blumenthal-Barby
Journal:  Ethics Hum Res       Date:  2019-11

8.  Time to Engage Young People in HIV Cure Research.

Authors:  Parya Saberi; Chadwick K Campbell; Manuel Venegas; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2021-04-01       Impact factor: 2.205

Review 9.  Ethics of HIV cure research: an unfinished agenda.

Authors:  Karine Dubé; John Kanazawa; Jeff Taylor; Lynda Dee; Nora Jones; Christopher Roebuck; Laurie Sylla; Michael Louella; Jan Kosmyna; David Kelly; Orbit Clanton; David Palm; Danielle M Campbell; Morénike Giwa Onaiwu; Hursch Patel; Samuel Ndukwe; Laney Henley; Mallory O Johnson; Parya Saberi; Brandon Brown; John A Sauceda; Jeremy Sugarman
Journal:  BMC Med Ethics       Date:  2021-06-30       Impact factor: 2.834

Review 10.  The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.

Authors:  John T Kanazawa; Parya Saberi; John A Sauceda; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2020-12-07       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.